Clotilde sells ATHN 128.23: Dan Haley has been named General Counsel, effective immediately, replacing Daniel Orenstein, who is leaving the company to pursue new professional opportunities.

Cosinuke will remain in his current role until the end of year, continuing to work closely with Mr. O'Brien has managed integration efforts between Epocrates and athenahealth, a responsibility he will maintain. Tim O'Brien will become Chief Marketing Officer, effective January 2016. In this role, he will lead all marketing and Epocrates initiatives, using his leadership experience in operations as athenahealth scales. With a potentially expanding range for what is considered appropriate for hypertension treatment, providers can expect an increase in patients who could benefit from more active management. The company is now developing tools that would allow interested physicians to identify these individuals and bring them in for further assessment.


Bambi:
Insider Selling: athenahealth EVP Stephen N.

Raeann:
The Business provides cloud-based services for revenue cycle management and medical billing, electronic health records ( NASDAQ:ATHN ), patient engagement, care coordination, population health management, also as clinical intelligence and decision support.

Jamika:
Finally, Topeka Capital Markets dropped their target price on shares of athenahealth from $152.00 to $150.00 and set a buy rating on the stock in a report on Friday, June 12th.

Demetria:
They set a hold rating and a $125.00 price target on the stock.

Paola:
Canaccord Genuity assumed coverage on shares of athenahealth in a research report on Thursday, July 16th.

Renay:
They issued an outperform rating and a $168.00 target price for the company.

Salena:
Oppenheimer assumed coverage on shares of athenahealth in a research note on Wednesday, June 17th.

Daryl:
They set an outperform rating and a $168.00 target price for the company.

Jetta:
Stephens started coverage on shares of athenahealth in a report on Thursday, June 18th.

Melvin:
ATHN has been the subject of a number of other research reports.

Athenahealth (NASDAQ:ATHN)
//stockhand.net/us/?q=nasdaq%3Aathn&id=559634